Vestal Point Capital LP Sells 205,000 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Vestal Point Capital LP lowered its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 34.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 395,000 shares of the company’s stock after selling 205,000 shares during the period. Vestal Point Capital LP owned about 1.33% of Dianthus Therapeutics worth $10,815,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Quest Partners LLC raised its position in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Dianthus Therapeutics in the second quarter worth approximately $112,000. MetLife Investment Management LLC lifted its stake in shares of Dianthus Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after acquiring an additional 7,854 shares during the period. American Century Companies Inc. boosted its holdings in Dianthus Therapeutics by 38.6% in the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after acquiring an additional 8,473 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $236,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

DNTH opened at $23.83 on Friday. Dianthus Therapeutics, Inc. has a 1-year low of $6.58 and a 1-year high of $33.77. The company’s fifty day moving average price is $26.82 and its two-hundred day moving average price is $26.59.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Oppenheimer upped their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Raymond James increased their price target on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Wedbush dropped their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.